Taupin Philippe
National Neuroscience Institute, National University of Singapore, 11 Jalan Tan Tock Seng, Singapore.
Curr Opin Mol Ther. 2006 Apr;8(2):156-63.
HuCNS-SC, a proprietary human neural stem cells product, is being developed as a cellular therapy for the potential treatment of Batten disease, one of a group of disorders known as neural ceroid lipofuscinoses (NCL). Developer StemCells is also investigating the therapy for spinal cord injury and other central nervous system disorders, such as demyelinating disease, stroke and Alzheimer's disease. A phase I trial of HuCNS-SC for infantile and late-infantile NCL has been initiated, following the March 2006 U.S. Food and Drug Administration approval of StemCells' investigational new drug application.
HuCNS-SC是一种专利性的人类神经干细胞产品，正作为一种细胞疗法进行开发，用于潜在治疗贝敦氏病，这是一组被称为神经蜡样脂褐质沉积症（NCL）的疾病之一。研发公司StemCells也在研究该疗法用于治疗脊髓损伤和其他中枢神经系统疾病，如脱髓鞘疾病、中风和阿尔茨海默病。2006年3月美国食品药品监督管理局批准了StemCells的新药临床试验申请后，针对婴儿型和晚发型NCL的HuCNS-SC一期试验已启动。
